By the Top Tier Newswire AI Desk · August 19, 2026 at 10:24 PM ET · reviewed against 6 wire stories
BIONTECH SE ADR (BNTX) is up +21.96% in the latest session. Our newswire has captured 6 stories on BNTX across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why BNTX stock is up today
BioNTech SE ADR (BNTX) surged 21.96% to $113.12 on Wednesday, driven by a broad biotech rally following a Phase 3 trial success for an mRNA-based cancer vaccine developed by Moderna and Merck. The development reignited investor interest in the mRNA space, particularly in companies like BioNTech that pioneered similar technology. The stock opened with a 13.2% gap up and reached a session high of $116.00 before settling near $113.12.
What Happened
The rally was sparked by Moderna’s announcement of a major milestone in its partnership with Merck for an mRNA-based cancer treatment. This success triggered a sector-wide response, with BioNTech, Arcturus, and other biotech firms seeing significant gains. The news also lifted biotech ETFs and drew attention from high-profile figures including Jim Cramer and Elon Musk. BioNTech’s stock, which had previously led the mRNA vaccine charge, was among the most active in the rally.
Analysts at Leerink noted the momentum may not be sustainable, suggesting the gains could fade as the market digests the news. Meanwhile, the stock’s intraday performance reflected strong early buying pressure, with volume reaching 7.1 million shares by midday, more than seven times its 3-month average.
What The Data Shows
BioNTech’s stock opened at $105.01 and traded as low as $99.00 before climbing to a high of $116.00. The stock is currently trading within its 52-week range of $79.52 to $124.00. Unusual options activity was noted, with $274K in call premiums exchanged compared to $166K in put premiums. On the 52-week tape, the stock printed 12 fresh 52-week highs and 3 lows on August 19, 2026.
What To Watch
Investors should monitor coverage breadth and analyst commentary in the coming days to gauge whether the momentum holds. No earnings date is scheduled for the near term, but continued developments in the mRNA cancer vaccine space could influence the stock’s trajectory.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BNTX · Aug 19 session (5-min) · +21.29% vs prior close · updated 10:23 PM ETAI sentiment, last 36h · averaged over 6 stories · 63/100 bullish
The headlines behind the move
Story flow · 6 stories on the wire, last 36h · hover or tap a dot for the headline
24d agoStocktwits NewsBULLISH 73Product/PR
Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough
The breakthrough sparked a broad biotech rally, lifting Merck, BioNTech, Arcturus, cancer-treatment developers, gene-editing stocks and biotech ETFs.
24d agoBarron'sBULLISH 64Product/PR
BioNTech Stock Surges 20% on Moderna Cancer Vaccine Win. Why the Gains Could Fade.
BioNTech, a former pioneer of mRNA cancer vaccines, was part of a broad rally Wednesday. Leerink analysts don’t expect the momentum to last.
24d agoSeeking AlphaNEUTRAL 54General
BioNTech’s rally on Moderna trial win likely to fade, Leerink says
BioNTech (BNTX) stock rose after a Phase 3 trial win for an mRNA-based cancer shot from Moderna (MRNA) and Merck (MRK), a rally Leerink expects to fade. Read more here.
24d agoThe FlyBULLISH 72General
BioNTech rises 20.3%
24d agoThe FlyBULLISH 62General
BioNTech rises 21.6%
24d agoInvesting.com MarketsNEUTRAL 50General
Why is BioNTech stock surging today?
Why is BioNTech stock surging today?
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →